ATHA
Athira Pharma Inc.
$4.53
-$0.23(-4.94%)
45
Overall
60
Value
54
Tech
23
Quality
Market Cap
$15.42M
Volume
28.08K
52W Range
$2.20 - $7.00
Target Price
$4.00
Company Overview
| Mkt Cap | $15.42M | Price | $4.53 |
| Volume | 28.08K | Change | -4.94% |
| P/E Ratio | -0.2 | Open | $4.86 |
| Revenue | -- | Prev Close | $4.76 |
| Net Income | $-96.9M | 52W Range | $2.20 - $7.00 |
| Div Yield | N/A | Target | $4.00 |
| Overall | 45 | Value | 60 |
| Quality | 23 | Technical | 54 |
No chart data available
About Athira Pharma Inc.
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Latest News
Athena Gold Launches $2 Million Private Placement for Exploration Expansion
TipRanks Canadian Auto-Generated Newsdesk•4 days ago
Athena Gold Expands Landholding at Excelsior Springs Project
TipRanks Canadian Auto-Generated Newsdesk•10 days ago
Athena Gold Reports High-Grade Discoveries at Excelsior Springs Project
TipRanks Canadian Auto-Generated Newsdesk•11 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATHA | $4.53 | -4.9% | 28.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |